CurrentEndo — Type 1 diabetes

Lived experiences of type 1 diabetes and disordered eating: Insights for prevention and early intervention in Paediatric care

2026-11-13T22:45:40.907Z

Cohort study · Diabet Med, 2026.

Current Diabetes Technologies and Everyday School Life of Children and Adolescents with Type 1 Diabetes: Did We Do Our Homework?

2026-11-13T19:45:41.967Z

Cross-sectional study · Horm Res Paediatr, 2026.

The transition from childhood to adulthood in diabetes care: A qualitative evidence synthesis

2026-11-13T19:45:41.967Z

Meta-analysis · Diabet Med, 2026.

Transient Cognitive Vulnerability After Hypoglycemia in Adults With Type 1 Diabetes: Evidence From Continuous Glucose Monitoring and Cognitive Ecologic Momentary Assessment

2026-11-13T19:45:41.967Z

Research article · Diabetes Care, 2026.

Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes

2026-11-13T18:46:09.627Z

Guideline or statement · Diabetes Care, 2026.

Evaluating the effectiveness of the D1 Now intervention to improve outcomes among young adults with type 1 diabetes: Protocol for a cluster randomised controlled trial

2026-11-13T18:46:09.627Z

Trial design · Diabet Med, 2026.

It's All One Trial: a continuous master-protocol framework to accelerate development and confirmation of disease-modifying therapies for type 1 diabetes

2026-11-13T18:46:09.627Z

Cohort study · Diabetologia, 2026.

Assessing the Utility of a Capillary-Adjusted Oral Glucose Tolerance Test for the Early Detection of Type 1 Diabetes in Childhood

2026-11-13T17:46:43.542Z

Diagnostic or prognostic study · Diabetes Technol Ther, 2026.

Effectiveness of various balanced electrolyte solutions in the resuscitation of patients with diabetic ketoacidosis: A pairwise meta-analysis and network meta-analysis

2026-11-13T17:46:43.542Z

Meta-analysis · Diabetes Res Clin Pract, 2026.

Menstrual phase variations in glycemic control and insulin requirements in females with type 1 diabetes: A systematic review and meta-analysis

2026-11-13T17:46:43.542Z

Meta-analysis · Diabetes Res Clin Pract, 2026.

The never‐asked: Understanding the gap in emotional support for people living with diabetes

2026-11-13T17:00:16.153Z

Cross-sectional study · Diabet Med, 2026.

Diabetic Ketoacidosis: Systematic Review and Meta‐Analysis

2026-11-13T15:47:59.646Z

Meta-analysis · Diabetes Obes Metab, 2026.

Fetal, placental and amniotic fluid volume across gestation in women with type 1 diabetes: a prospective MRI study

2026-11-13T15:47:59.646Z

Cohort study · Diabetologia, 2026.

Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial

2026-11-13T10:59:26.873Z

Randomized controlled trial · JAMA, 2023. Mean C-peptide AUC, 52 weeks: Intensive management mean 0.45 pmol/mL; baseline 0.57 pmol/mL · Standard care mean 0.50 pmol/mL; baseline 0.60

Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial

2026-11-13T10:59:26.873Z

Randomized controlled trial · JAMA, 2023. Mean C-peptide AUC, 52 weeks: Verapamil mean 0.65 pmol/mL · Placebo mean 0.44 pmol/mL

Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact

2026-11-13T10:58:58.035Z

Guideline or statement · Lancet, 2023.

Glucagon‐like peptide‐1 agonists combined with sodium‐glucose cotransporter‐2 inhibitors reduce weight in type 1 diabetes

2026-11-13T10:47:54.884Z

Cohort study · Obesity (Silver Spring), 2023. Percentage weight loss, 12 months: SGLT2i mean 4.4% ± 6.0% · GLP1-RA mean 8.2% ± 8.5% · Combo mean 9.0% ± 8.4%

Can HbA1c Alone Be Safely Used to Guide Insulin Therapy in African Youth with Type 1 Diabetes?

2026-11-13T10:46:56.512Z

Cross-sectional study · Pediatr Diabetes, 2023. HbA1c vs MBG: Regression equation, African cohort MBG (mg/dL) = 32.0 + 16.73 × HbA1c (%), r = 0.55, p < 0.0001

Dietary Intake and Body Mass Index Influence the Risk of Islet Autoimmunity in Genetically At-Risk Children: A Mediation Analysis Using the TEDDY Cohort

2026-11-13T10:46:56.512Z

Cohort study · Pediatr Diabetes, 2023. Development of IA (indirect effect via BMI): Indirect effect of total energy intake (kcal/day) 0.13 [0.05, 0.21]

DNA Methylation Near DLGAP2 May Mediate the Relationship between Family History of Type 1 Diabetes and Type 1 Diabetes Risk

2026-11-13T10:46:56.512Z

Case-control study · Pediatr Diabetes, 2023. Mediation via methylation at cg00565786: affected mother vs no family history: Pure natural indirect effect, OR 1.98 (95% CI 1.06-3.71)

Glycated Hemoglobin is a Significant Predictor of Femoral, but Not of Carotid or Popliteal, Intima-Media Thickness in Adolescents with Type 1 Diabetes: A Case-Series Study

2026-11-13T10:46:56.512Z

Research article · Pediatr Diabetes, 2023. IMT by arterial site: HbA1c >10% vs ≤10%: thicker femoral IMT, but not carotid or popliteal IMT

High Rate of Islets Autoimmunity in Pediatric Patients with Index Admission of Acute Pancreatitis

2026-11-13T10:46:56.512Z

Cohort study · Pediatr Diabetes, 2023. Positive for ≥1 of 4 islet cell autoantibodies (IAA, GADA, IA-2A, ZnT8A) 24 (29%)

Household Food Insecurity and Cognition in Youth and Young Adults with Youth-Onset Diabetes

2026-11-13T10:46:56.512Z

Cross-sectional study · Pediatr Diabetes, 2023. Composite Fluid Cognition score (T1D) — Food-insecure vs Food-secure: β -2.5 (95% CI -4.8, -0.1); lower with food insecurity; T1D; attenuated to non-significance after adjustment for demographics

Increased Use of Hyperosmolar Therapy for Suspected Clinically Apparent Brain Injury in Pediatric Patients with Diabetic Ketoacidosis during the Peak of the COVID-19 Pandemic

2026-11-13T10:46:56.512Z

Cohort study · Pediatr Diabetes, 2023. Hyperosmolar therapy for suspected CABI — Pandemic vs Prepandemic; P = 0.014; significantly higher during the pandemic

Perceived Knowledge and Confidence for Providing Youth-Specific Type 1 Diabetes Exercise Recommendations amongst Pediatric Diabetes Healthcare Professionals: An International, Cross-Sectional, Online Survey

2026-11-13T10:46:56.512Z

Cross-sectional study · Pediatr Diabetes, 2023. ISPAD exercise guidelines familiar 68/125 (54%)

School-Based Diabetes Care: A National Survey of U.S. Pediatric Diabetes Providers

2026-11-13T10:46:56.512Z

Cross-sectional study · Pediatr Diabetes, 2023. Provider practices, attitudes and beliefs on school-based diabetes care (SBDC): Indicated SBDC was very important 95%

Sedentary Behavior and Physical Activity Associated with Psychosocial Outcomes in Adolescents with Type 1 Diabetes

2026-11-13T10:46:56.512Z

Secondary analysis · Pediatr Diabetes, 2023. Diabetes distress: MVPA associated with lower diabetes distress, unadjusted -3.6 (95% CI: -6.4 to -0.8)

The Frequency of Undiagnosed Celiac Disease in Youth with Type 1 Diabetes and Its Association with Diabetic Retinopathy: The SEARCH for Diabetes in Youth Study

2026-11-13T10:46:56.512Z

Cross-sectional study · Pediatr Diabetes, 2023. Frequency of CD: Reported CD 7% · Seropositive for CD 4% · Potentially undiagnosed CD 1.2%

Diabetes Device Downloading: Benefits and Barriers Among Youth With Type 1 Diabetes

2026-11-13T10:44:19.723Z

Cross-sectional study · J Diabetes Sci Technol, 2021. Retrospective reviewers vs Non-reviewers: child age; P = .0001; younger child age with review (12.2 versus 15.4)

Ecological Momentary Assessment of Positive and Negative Affect and Associations with Blood Glucose in Teens with Type 1 Diabetes

2026-11-13T10:44:19.723Z

Research article · J Diabetes Sci Technol, 2021. Associations of affect with BG: HbA1c ≤8%: positive affect and in-range BG, OR 1.08 (1.04-1.13), P = .0002 (95% CI)

Effects of Aerobic Exercise on Systemic Insulin Degludec Concentrations in People with Type 1 Diabetes

2026-11-13T10:44:19.723Z

Cohort study · J Diabetes Sci Technol, 2021. Systemic IDeg concentration vs baseline, during 60-minute exercise: Systemic IDeg increased during exercise over time vs baseline P < .001

Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes

2026-11-13T10:44:19.723Z

Randomized controlled trial · J Diabetes Sci Technol, 2022. days 5, 7 and 10 vs day 3 — LY900027 vs Insulin lispro; AUCIns.0-5h did not differ significantly between treatments

Glycemia Risk Index Assessment in a Pediatric and Adult Patient Cohort With Type 1 Diabetes Mellitus

2026-11-13T10:44:19.723Z

Cross-sectional study · J Diabetes Sci Technol, 2023. GRI: Pediatric 48.0 ± 22.2 · Adults 56.8 ± 23.4 · CSII 51.0 ± 15.3 · MDI 55.0 ± 25.4

Glycemic Risk Index Profiles and Predictors Among Diverse Adults With Type 1 Diabetes

2026-11-13T10:44:19.723Z

Cross-sectional study · J Diabetes Sci Technol, 2023. Mean glucose and variability, TIR, and % time in high and very high glucose ranges differed across the five GRI zones P values < .001

Observed Characteristics Associated with Diabetes Device Use Among Teens with Type 1 Diabetes

2026-11-13T10:44:19.723Z

Cross-sectional study · J Diabetes Sci Technol, 2021. Device use, baseline: Pump users 65%

Patient Demographics and Clinical Outcomes Among Type 1 Diabetes Patients Using Continuous Glucose Monitors: Data From T1D Exchange Real-World Observational Study

2026-11-13T10:44:19.723Z

Cohort study · J Diabetes Sci Technol, 2021. CGM use: CGM users 48%

The Use of Extreme Value Statistics to Characterize Blood Glucose Curves and Patient Level Risk Assessment of Patients With Type I Diabetes

2026-11-13T10:44:19.723Z

Research article · J Diabetes Sci Technol, 2021. High-risk patients identified with novel metrics: High-risk patients (estimated time above 600 mg/dL per year >2 hours) 9

Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)

2026-11-13T10:42:28.137Z

Randomized controlled trial · Diabetes Technol Ther, 2023. TBR<70, 24 h postexercise: IGlar U300 (100%) mean 2.71 (SE 0.51) % · IDeg U100 (100%) mean 4.37 (SE 0.69) % · IGlar U300 (75%) mean 2.28 (SE 0.53) % · IDeg U100 (75%) mean 2.55 (SE 0.58) %

Disparities in Continuous Glucose Monitoring Use Among Women of Reproductive Age with Type 1 Diabetes in the T1D Exchange

2026-11-13T10:42:28.137Z

Cohort study · Diabetes Technol Ther, 2023. CGM use: 2015 20.6% · 2018 30.0%

Mediating Effects of Technology-Based Therapy on the Relationship Between Socioeconomic Status and Glycemic Management in Pediatric Type 1 Diabetes

2026-11-13T10:42:28.137Z

Cross-sectional study · Diabetes Technol Ther, 2022. HbA1c, Q5 vs Q1, and mediation by technology use — Q5 vs Q1: difference +1.17 %; P < 0.0001

MiniMed 780G Six-Month Use in Children and Adolescents with Type 1 Diabetes: Clinical Targets and Predictors of Optimal Glucose Control

2026-11-13T10:42:28.137Z

Cohort study · Diabetes Technol Ther, 2023. Achievement of clinical targets (aggregated data), entire study period: Time in range (TIR) >70% achieved 72.1%

Hypoglycemia and glycemic variability of people with type 1 diabetes with lower and higher physical activity loads in free-living conditions using continuous subcutaneous insulin infusion with predictive low-glucose suspend system

2026-11-13T10:41:04.791Z

Cohort study · BMJ Open Diabetes Res Care, 2023. Glycemic variability and time in ranges, 14 days — HL vs LL; p≤0.05; More time below range (TBR) during night hours with HL

TXNIP DNA methylation is associated with glycemic control over 28 years in type 1 diabetes: findings from the Pittsburgh Epidemiology of Diabetes Complications (EDC) study

2026-11-13T10:41:04.791Z

Cohort study · BMJ Open Diabetes Res Care, 2023. DNA methylation at cg19693031 (TXNIP) and cg21534330 (Casein Kinase 1 Isoform Delta) significantly inversely associated with concurrent HbA1c

Incidence of new-onset type 1 diabetes during Covid-19 pandemic: A French nationwide population-based study

2026-11-13T10:39:51.606Z

Cohort study · Diabetes Metab, 2023. Hospitalizations for new-onset T1D: Apart from a decrease during the 2020 lockdown, number of hospitalizations for new-onset T1D not significantly different in 2020 and 2021 vs 2019

Maternal autoimmune disease associated with a higher risk of offspring with type 1 diabetes: A nationwide mother-child cohort study in Taiwan

2026-11-13T10:39:51.606Z

Cohort study · Diabetes Metab, 2023. Childhood-onset T1D — Maternal autoimmune disease vs No maternal autoimmune disease: aHR 1.55 (95% CI 1.16-2.08)

Parental history of psychiatric disorders and risk of type 1 diabetes in the offspring

2026-11-13T10:39:51.606Z

Cohort study · Diabetes Metab, 2022. T1D in offspring — Maternal psychiatric disorder vs No maternal psychiatric disorder: incidence RR 1.10 (95% CI 1.01-1.20)

Adherence in Diabetes Questionnaire (ADQ) score as predictor of 11-year HbA1c trajectories in children and adolescents with type 1 diabetes: A population-based longitudinal study

2026-11-13T10:35:20.262Z

Cohort study · Diabetes Res Clin Pract, 2023. HbA1c trajectory membership, 11 years: Group 1 27% · Group 2 39% · Group 3 25% · Group 4 9%

Association of type 1 diabetes mellitus and risk of atrial fibrillation: Systematic review and meta-analysis

2026-11-13T10:35:20.262Z

Meta-analysis · Diabetes Res Clin Pract, 2023. AF risk — T1D vs Control: HR 1.30 (95% CI 1.15-1.47); pooled; higher with T1D

Central nervous system microstructural alterations in Type 1 diabetes mellitus: A systematic review of diffusion Tensor imaging studies

2026-11-13T10:35:20.262Z

Meta-analysis · Diabetes Res Clin Pract, 2023. CNS microstructure on DTI: Most studies: reduced FA widespread in optic radiation, corona radiata, corpus callosum and other frontal, parietal and temporal regions in adults

Circulating metabolomic and lipidomic changes in subjects with new-onset type 1 diabetes after optimization of glycemic control

2026-11-13T10:35:20.262Z

Cohort study · Diabetes Res Clin Pract, 2023. Serum lipidomic and metabolomic changes, after 2-6 months: Identified lipids changed 51